Avidity Biosciences Inc (NYSE: RNA) — Perfil da empresa, notícias e dados financeiros
Avidity Biosciences develops RNA-based therapies targeting diseases like muscular dystrophy, focusing on targeted oligonucleotide delivery.
Avidity Biosciences Inc
Avidity Biosciences Inc is a biopharmaceutical company focused on developing a novel class of RNA therapeutics called Antibody Oligonucleotide Conjugates. The company's proprietary platform combines the targeted specificity of monoclonal antibodies with the precision of oligonucleotide therapies to deliver genetic medicines to previously inaccessible tissues and cells, primarily targeting rare neuromuscular diseases. Its lead clinical development programs address rare genetic muscle disorders, including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. Additionally, the company is expanding its preclinical research pipeline into cardiology and other rare disease indications to address fundamental genetic drivers of disease.
Resumo
Operações
Produtos e/ou serviços de Avidity Biosciences Inc
- Myotonic Dystrophy Type 1 Therapeutics: Development of antibody oligonucleotide conjugate therapies designed to deliver small interfering RNA directly to skeletal and cardiac muscle tissues to reduce toxic DMPK messenger RNA levels for treating myotonic dystrophy type 1.
- Facioscapulohumeral Muscular Dystrophy Therapeutics: Clinical stage antibody oligonucleotide conjugate therapeutics designed to selectively reduce DUX4 gene expression in skeletal muscle tissue to prevent muscle degeneration and improve functional outcomes in patients with facioscapulohumeral muscular dystrophy.
- Duchenne Muscular Dystrophy Exon 44 Therapeutics: Development of phosphorodiamidate morpholino oligomer conjugates designed to promote exon 44 skipping in dystrophin pre-mRNA, targeting dystrophin production restored directly in skeletal and cardiac muscle cells for Duchenne muscular dystrophy.
- Cardiology Targeted RNA Therapeutics: Preclinical research and drug development focused on delivering oligonucleotide therapies directly to cardiac muscle cells to address genetic cardiac diseases, including targeted therapies for genetic cardiomyopathies and related heart conditions.
- Antibody Oligonucleotide Conjugate Platform: Proprietary platform technology combining the tissue targeting specificity of monoclonal antibodies with the synthetic precision of oligonucleotide therapeutics to deliver genetic medicines into previously inaccessible cell types and internal tissue targets.
- Rare Neuromuscular Disease Pipeline: Early-stage research and discovery programs expanding antibody oligonucleotide conjugate applications into additional rare skeletal muscle disorders, aimed at selectively downregulating disease-causing messenger RNAs or restoring functional protein expression in human tissue.
equipe executiva do Avidity Biosciences Inc
- Kathleen P. GallagherPresident, CEO & Director
- Brendan WinslowChief Financial Officer
- Husam YounisChief Scientific Officer
- Stephanie KenneyChief Corporate Affairs Officer
- Steven George HughesChief Medical Officer
- Rocio Martin HoyosChief Strategy Officer
Últimas notícias sobre a Avidity Biosciences Inc
Principais indicadores financeiros
Resultados divulgados pela Avidity Biosciences Inc, em USD.
- Cap. de mercado
- 143,7 mi
- Receita (TTM)
- 35,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -5.4
- Dividend yield
- —
- Margem de lucro
- -184.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 18,6 mi | -76,8 mi | -76,7 mi | |
| 10,9 mi | -378,9 mi | -322,3 mi | |
| 9,6 mi | -235,6 mi | -212,2 mi | |
| 9,2 mi | -178,9 mi | -169,1 mi |